Who owns GenPath?
Who owns GenPath?
BioReference Laboratories
GenPath is a Division of BioReference Laboratories, a Subsidiary of OPKO Health.
How many locations does BioReference have?
Our Company BioReference is the largest full service specialty laboratory offering a comprehensive list of laboratory services. With specialized divisions, 11 laboratory locations, over 200 Patient Service Centers and more than 4,000 employees nationwide, BioReference is a preferred choice for laboratory personnel.
How many BioReference labs are there?
About BioReference Laboratories, Inc. The company is in network with the five largest health plans in the United States, operates a network of 11 laboratory locations, and is backed by a medical staff of more than 160 MD, PhD and other professional level clinicians and scientists.
How long do BioReference results take?
BioReference Laboratories: While there had been a backlog in its facilities, the company said it has cleared it within a week of making their testing for Covid-19 available and cut its turnaround time to 24 hours for inpatients and 48 to 72 hours for the general public.
What does opko Health do?
OPKO Health is a medical test and medication company focused on diagnostics and pharmaceuticals. The company is a publicly traded company on NASDAQ and TASE under the symbol “OPK”.
How many employees does BioReference have?
BioReference Laboratories, Inc. has 4,347 employees and is ranked lowest among it’s top 10 competitors.
Where is opko Health located?
Miami, Florida
OPKO Health is a medical test and medication company focused on diagnostics and pharmaceuticals….OPKO Health.
| Type | Public |
|---|---|
| Headquarters | Miami, Florida |
| Products | Medical Products |
| Number of employees | 6,096 |
| Website | www.opko.com |
Who owns Bio Reference Lab?
OPKO Health
Bio-Reference Laboratories, Inc./Parent organizations
BioReference Laboratories, Inc. is a wholly owned subsidiary of OPKO Health, Inc. OPKO Health is a diversified healthcare company that seeks to establish industry leading positions in large, rapidly growing markets.
How accurate is the BioReference antibody test?
One chart that summarizes the accuracy of antibody screening New York is using a test from BioReference with a listed sensitivity of 91.2% and specificity of 97.3% for some of the screenings.
Who owns OPKO Health company?
Dr. Phillip Frost
At OPKO Health, the entrepreneurial acumen of our founder and CEO, Dr. Phillip Frost, has led to the development of a diverse healthcare company flexible enough to adapt to evolving patient needs.
Is OPKO Health A Good Investment?
OPKO Health has received a consensus rating of Buy. The company’s average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.
Is OPK a good stock to buy?
The consensus among Wall Street equities research analysts is that investors should “buy” OPKO Health stock.
Where to find GenPath diagnostics in New Jersey?
To find a patient service center nearest you, please input your city or zip code in the location finder below: Visit Our Other Sites BioReference Laboratories, Inc. GeneDx, Inc. 4Kscore® my·labology Scarlet Health ™ Headquarters 481 Edward H. Ross Dr. Elmwood Park, NJ 07407-0621 GenPath Urology & Oncology (800) 627-1479 GenPath Women’s Health
How to contact GenPath urology and oncology office?
GenPath Urology & Oncology (800) 627-1479 GenPath Women’s Health (800) 633-4522 Stay Connected GenPath Urology & Oncology
Do you need an appointment to see GenPath?
Locations Find a testing location GenPath utilizes the BioReference Laboratories Patient Service Center network to meet patient’s testing needs. No appointments are necessary and each location offers the following services and more:
Who is Bioreference Laboratories and what is GenPath?
ELMWOOD PARK, N.J., September 2, 2020 — BioReference Laboratories, Inc., an OPKO Health company (NASDAQ:OPK), along with its specialty oncology division, GenPath, today announced the launch of OnkoSight AdvancedTM, a next-generation sequencing (NGS) assay that enables revolutionary deoxyribonucleic acid (DNA) mutational profiling of tumor samples.
